Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREPOSTEROUS trial
2024-519726-20-00Phase 4Authorised
- Sponsor
- Oslo University Hospital
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of dalteparin and enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Venous thromboembolisms within 30 days. Planned start Dec 2024; status: authorised.
02
Drugs
dalteparinenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2024-519726-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519726-20-00.